In lung transplantation, using lungs from donors who are considered high risk for certain infectious diseases has similar outcomes as using lungs from donors with standard risk.
The highest survival was seen with the induction maintenance combination of sirolimus plus tacrolimus without induction therapy.
The Xvivo Perfusion System can temporarily ventilate, oxygenate, and pump preservation solution through lungs previously deemed unacceptable for transplant.
No meaningful associations were detected in procedural listing preferences and survival outcomes in patients with COPD or interstitial lung disease awaiting lung transplant.
In patients with pulmonary arterial hypertension who were treated with a parenteral prostanoid, survival was linked with the number of guideline-recommended lower-risk and higher-risk criteria attained.
Underlying cystic fibrosis may be a risk factor for the prediction of delayed gastric emptying in patients who undergo lung transplantation.
A retrospective cohort study examined squamous cell carcinoma outcomes in adult lung transplant recipients who received voriconazole.
